Rare and Common Genetic Variation Underlying Atrial Fibrillation Risk
JAMA Cardiology
JUNE 25, 2024
This genetic association study evaluates the association of genetic variants with atrial fibrillation, cardiomyopathy, and heart failure.
Catheter ablation in patients with atrial fibrillation and dilated cardiomyopathy
Frontiers in Cardiovascular Medicine
JANUARY 16, 2024
Introduction Catheter ablation is an effective and safe strategy for treating atrial fibrillation patients. Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. Among the catheter ablation group, 58.7% ( n = 27) had persistent atrial fibrillation.
Ventricular Fibrillation, ICD, LBBB, QRS of 210 ms, Positive Smith Modified Sgarbossa Criteria, and Pacemaker-Mediated Tachycardia
Dr. Smith's ECG Blog
APRIL 2, 2024
So it must be atrial fibrillation. Answer : it is irregularly irregular and the initial part of the QRS is fast, so this is atrial fibrillation with Left Bundle Branch Block (LBBB). Patient has an ICD, which is primarily placed in patients with cardiomyopathy. What do you think? mm; the S-wave is 18 mm.
Tachycardia 
135
135 
Atrial dilatation in Atrial fibrillation : A query with multiple twists!
Dr. S. Venkatesan MD
APRIL 28, 2024
When atrial fibrillation (AF) begins, it can start with a single focus, degenerating to multiple wavelets, and it spreads throughout the entire surface area of both atria. A fibrillatory wave that occurs at a rate of more than 600 beats per minute can cause fatigue in the long run, leading to atrial dilation.
Wide Complex Tachycardia -- VT, SVT, or A Fib with RVR? If SVT, is it AVNRT or AVRT?
Dr. Smith's ECG Blog
MARCH 28, 2024
male with pertinent past medical history including Atrial fibrillation, atrial flutter, cardiomyopathy, Pulmonary Embolism, and hypertension presented to the Emergency Department via ambulance for respiratory distress and tachycardia. Of course, this is NOT atrial fib, but rather PSVT, and so adenosine should work.
Tachycardia 130
130 
ECG Cases 45 ECG in Weakness and Neurological Symptoms
ECG Cases
SEPTEMBER 12, 2023
The post ECG Cases 45 ECG in Weakness and Neurological Symptoms appeared first on Emergency Medicine Cases.
Dysrhythmia 129
129 
Author’s Reply to Impact of Mavacamten on Atrial Fibrillation in Patients with Obstructive Hypertrophic Cardiomyopathy
HeartRhythm
JANUARY 23, 2025
We thank Hundal and colleagues for their letter1 regarding our analysis of the incidence of new-onset and progressive atrial fibrillation (AF) in mavacamtent-treated patients with obstructive hypertrophic cardiomyopathy (oHCM)2.
To the Editor—Impact of mavacamten on atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy
HeartRhythm
JANUARY 23, 2025
study on the frequency of new-onset and recurrent atrial fibrillation (AF) events in patients with obstructive hypertrophic cardiomyopathy (oHCM) on mavacamten.1 We read with interest Castrichini et al.s
Left atrial function during exercise stress echocardiography as a sign of paroxysmal/persistent atrial fibrillation
Cardiovascular Ultrasound
NOVEMBER 3, 2024
Atrial cardiomyopathy is closely associated with atrial fibrillation (AF), and some patients exhibit no dysfunction at rest but demonstrate evident changes in left atrial (LA) function and LA volume during exe.
Catheter Ablation of Atrial Fibrillation in Infiltrative Cardiomyopathies: A Narrative Review
Journal of Cardiovascular Electrophysiology
NOVEMBER 7, 2024
Catheter ablation of atrial fibrillation in infiltrative cardiomyopathies ABSTRACT Atrial and ventricular arrhythmias are common in patients with Infiltrative heart diseases. Catheter ablation is a safe and effective modality for the treatment of AF in infiltrative cardiomyopathy.
Percutaneous Left Atrial Appendage Closure for Stroke Prevention in Hypertrophic Cardiomyopathy Patients with Atrial Fibrillation.
HeartRhythm
MAY 22, 2024
Percutaneous left atrial appendage closure (LAAC) is an effective alternative strategy for stroke prevention in atrial fibrillation (AF) patients at high risk for bleeding with anticoagulation (AC). Efficacy of this strategy in hypertrophic cardiomyopathy (HCM) remains uncertain.
Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy
European Journal of Heart Failure
DECEMBER 5, 2024
Oral diuretic intensification was significantly prognostic of mortality amongst patients with transthyretin cardiomyopathy and occurred more often than HF hospitalization. Patients experiencing ODI had higher rates of subsequent mortality (17.7 per 100 person-years; 95% confidence interval [CI] 13.323.7) per 100 person-years; 95% CI 17.750.3)
Outpatient 75
75 
PO-04-094 IMPROVED PREDICTION MODEL FOR RISK OF ATRIAL FIBRILLATION IN HYPERTROPHIC CARDIOMYOPATHY : LEAP-HCM SCORE
HeartRhythm
APRIL 30, 2024
Atrial fibrillation(AF) is associated with increased risk of embolic stroke and heart failure hospitalizations in patients with hypertrophic cardiomyopathy(HCM).
Top 10: Must-reads from the Month of May
DAIC
JUNE 4, 2024
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment 8.
PO-03-086 FACTORS ASSOCIATED WITH CARDIAC FUNCTION IMPROVEMENT AFTER CATHETER ABLATION IN PATIENTS WITH SUSPECTED ATRIAL FIBRILLATION-MEDIATED CARDIOMYOPATHY
HeartRhythm
APRIL 30, 2024
Catheter ablation is recommended in patients with suspected atrial fibrillation-mediated cardiomyopathy (AMC) for the recovery of cardiac function.
PO-04-131 ATRIAL FIBRILLATION RECURRENCE FOLLOWING CATHETER ABLATION IS HIGHER IN HYPERTROPHIC COMPARED TO OTHER CARDIOMYOPATHY TYPES – INSIGHTS FROM LGE-MRI FIBROSIS
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF) is highly prevalent in patients with hypertrophic cardiomyopathy (HCM) as well as other cardiomyopathy (CM) phenotypes.
Incidence of Newly Recognized Atrial Fibrillation in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Mavacamten
HeartRhythm
APRIL 12, 2024
Mavacamten is a cardiac myosin inhibitor that has been shown to reduce left ventricular outflow tract obstruction in obstructive hypertrophic cardiomyopathy (oHCM).1 1 In late-stage clinical trials, atrial fibrillation (AF) represented an adverse event in 2-4 % of the patients randomized to mavacamten.1,2
Prediction of new‐onset atrial fibrillation in patients with hypertrophic cardiomyopathy using machine learning
European Journal of Heart Failure
DECEMBER 18, 2024
Development of a machine learning model to predict new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy. Aims Atrial fibrillation (AF) is the most common sustained arrhythmia among patients with hypertrophic cardiomyopathy (HCM), leading to increased symptom burden and risk of thromboembolism.
Atrioventricular nodal ablation is an effective management strategy for atrial fibrillation in patients with hypertrophic cardiomyopathy
HeartRhythm
AUGUST 23, 2023
Atrial fibrillation (AF) is common in patients with hypertrophic cardiomyopathy (HCM) and can be challenging to manage. Atrioventricular nodal (AVN) ablation may be an effective management strategy for AF in these patients.
Treatment for atrial fibrillation in hypertrophic cardiomyopathy: Welcome back ablate and pace
HeartRhythm
SEPTEMBER 19, 2023
In patients with hypertrophic cardiomyopathy (HCM), atrial fibrillation (AF) poses significant clinical challenges because of its adverse impact on hemodynamics. AF, especially when accompanied by rapid ventricular responses, compromises atrial contraction and in turn increases diastolic filling of the left ventricle.
Risk factors of late arrhythmia recurrences during 12 months after catheter ablation of atrial fibrillation: Insight into atrial cardiomyopathy
HeartRhythm
DECEMBER 16, 2024
A gradual increase in arrhythmia recurrences during 12 months after catheter ablation (CA) of atrial fibrillation (AF) is still reported.1
Assessing the impact of atrial fibrillation on symptoms and quality of life in hypertrophic cardiomyopathy
Journal of Cardiovascular Electrophysiology
JANUARY 30, 2024
Abstract Introduction In hypertrophic cardiomyopathy (HCM), atrial fibrillation (AF) has historically been regarded to have a deleterious impact on clinical course, strongly associated with progressive heart failure (HF) symptoms. Results Among the 218 patients, 50 (23%) had a history of AF and comprise the primary study cohort.
PO-05-111 CLINICAL OUTCOMES OF CATHETER ABLATION FOR ATRIAL FIBRILLATION, ATRIAL FLUTTER, AND ATRIAL TACHYCARDIA IN WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: A PROPOSED TREATMENT STRATEGY FOR CATHETER ABLATION IN EACH ARRHYTHMIA
HeartRhythm
APRIL 30, 2024
Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is often accompanied by atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT), which are difficult to control because beta-blockers and antiarrhythmic drugs can worsen heart failure (HF).
Integrating machine learning approach to identify sleep-disordered breathing in hypertrophic cardiomyopathy
Heart BMJ
JUNE 25, 2024
Hypertrophic cardiomyopathy (HCM) stands as one of the most common inheritable myocardial disease and is often marked by its association with sudden cardiac death (SCD) in the young. 1 2 Traditionally, risk assessment in HCM has focused mainly on estimating the likelihood of SCD.
Thromboembolic Complications From Atrial Fibrillation and Atrial Flutter in Pediatrics and Young Adults: A Multicenter Study
Journal of Cardiovascular Electrophysiology
DECEMBER 2, 2024
ABSTRACT Background Atrial fibrillation and atrial flutter are relatively rare in young people and the incidence of thromboembolic complications is unknown. Structural heart disease (SHD) was present in 120 patients (57%) and 20 patients (10%) had a primary cardiomyopathy.
PO-04-089 ATRIAL MECHANICAL REMODELING COULD BE PREDICTABLE FOR NEWLY DEVELOPED ATRIAL FIBRILLATION IN PATIENTS WITH EMBOLIC STROKE WITH UNDETERMINED SOURCE
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF) has been known as a main cause of embolic stroke. Atrial mechanical remodeling presenting cardiomyopathy could lead to not only occur AF but also increase risk of thromboembolism.
PO-02-054 EARLY DETECTION OF ATRIAL FUNCTIONAL MITRAL REGURGITATION IN ATRIAL FIBRILLATION PATIENTS USING ECG AND DEEP LEARNING
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF), a common cardiac arrhythmia, often results in significant atrial remodeling, including atrial cardiomyopathy and dilatation. Notably, aFMR is linked to a higher recurrence rate of AF after catheter ablation.
UH Harrington Heart and Vascular Institute First in World to Implant Penditure Clip Using Minimally Invasive Approach
DAIC
JANUARY 8, 2024
A person’s LAA may create issues including atrial fibrillation and stroke. We have the extensive expertise to offer isolated minimally invasive left atrial appendage occlusion through left-sided video assisted surgery,” said Dr. Rushing, Director of the Surgical Atrial Fibrillation program at UH Harrington Heart & Vascular Institute.
Bicuspid/Mitral 124
124 Impact of Ablation on AF Burden and Symptoms in HCM
American College of Cardiology
OCTOBER 23, 2024
What is the impact of atrial fibrillation (AF) catheter ablation in patients with hypertrophic cardiomyopathy (HCM) on reduction in AF burden and symptoms?
Ablation 52
52 
Bi-atrial arrhythmogenic substrate in patients with hypertrophic obstructive cardiomyopathy
HeartRhythm
JANUARY 18, 2024
Atrial fibrillation (AF) in patients with hypertrophic obstructive cardiomyopathy (HOCM) may be caused by a primary atrial myopathy. Whether HOCM-related atrial myopathy affects mainly electrophysiological properties of the left atrium (LA) or also the right atrium (RA) has never been investigated.
Risk of Stroke and Incident Atrial Fibrillation in Patients in Sinus Rhythm With Non-Ischemic Dilated Cardiomyopathy
The American Journal of Cardiology
SEPTEMBER 26, 2024
Publication date: Available online 26 September 2024 Source: The American Journal of Cardiology Author(s): Eduard Ródenas-Alesina, Jordi Lozano-Torres, Pablo Eduardo Tobías-Castillo, Clara Badia-Molins, Maria Calvo-Barceló, Rosa Vila-Olives, Guillem Casas-Masnou, Aleix Olivella San Emeterio, Toni Soriano-Colomé, Rubén Fernández-Galera, Ana B Méndez-Fernández, (..)
Prognostic Value of Low Voltage Area Burden in Atrial Fibrillation
HeartRhythm
JANUARY 23, 2024
The EHRA/HRS/APHRS/SOLAECE Expert Consensus on Atrial Cardiomyopathies published in 2017 defined atrial cardiomyopathy as “any complex of structural, architectural, contractile, or electrophysiological changes affecting the atria.”1
Genetic Atrial Cardiomyopathies: Common Features, Specific Differences, and Broader Relevance to Understanding Atrial Cardiomyopathy
Circulation: Arrhythmia and Electrophysiology
NOVEMBER 29, 2023
Atrial cardiomyopathy is a condition that causes electrical and contractile dysfunction of the atria, often along with structural and functional changes. Atrial enlargement and atrial fibrillation are common complications of ASCM and are often the predominant clinical features.
Prognostic impact of atrial cardiomyopathy: Long-term follow-up of patients with and without low-voltage areas following atrial fibrillation ablation
HeartRhythm
DECEMBER 26, 2023
Atrial cardiomyopathy is known as an underlying pathophysiological factor in the majority of AF patients. Left atrial low-voltage areas (LVAs) are reported to coincide with fibrosis, and to likely represent atrial cardiomyopathy.
ATTR-ACT Post Hoc Analysis: AFib/AFL Not Predictive of Mortality in Patients With ATTR-CM
American College of Cardiology
MAY 6, 2024
Although atrial fibrillation/atrial flutter (AFib/AFL) are common manifestations of transthyretin amyloid cardiomyopathy (ATTR-CM), a post hoc analysis of the ATTR-ACT study, published April 30 in JACC: CardioOncology, found they do not predict all-cause mortality.
AFIB 54
54 
Case Report: A rare case of Noonan syndrome with multiple lentigines manifesting as cardiac enlargement
Frontiers in Cardiovascular Medicine
JANUARY 16, 2025
Characterized by multiple lentigines, hypertelorism, short stature, and hearing loss, its common cardiac manifestations include pulmonary stenosis, hypertrophic cardiomyopathy (HCM), atrial septal defect, and left-sided heart lesions.
Impact of Sodium‐Glucose Co‐Transporter 2 Inhibitors on Atrial Fibrillation Recurrence Post‐Catheter Ablation Among Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Journal of Cardiovascular Electrophysiology
JANUARY 9, 2025
ABSTRACT Atrial fibrillation (AF) is the most common cause of arrhythmia-induced cardiomyopathy. Effective management strategies include medical therapy for rate and rhythm control, catheter ablation (CA), and goal-directed medical therapy.
Predictive Value of Artificial Intelligence?Enabled Electrocardiography in Patients With Takotsubo Cardiomyopathy
Journal of the American Heart Association
FEBRUARY 23, 2024
BackgroundRecent studies have indicated high rates of future major adverse cardiovascular events in patients with Takotsubo cardiomyopathy (TC), but there is no well‐established tool for risk stratification. Journal of the American Heart Association, Ahead of Print.
Anticoagulation in Post-Operative AFib, Non-ST-Elevation Acute Coronary Syndromes, Arrhythmia-Induced Cardiomyopathy
American College of Cardiology
JUNE 5, 2024
In this week’s View, Dr. Eagle looks at anticoagulation for post-operative atrial fibrillation after isolated coronary artery bypass grafting. He then examines a meta-analysis of invasive vs. conservative management of non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting.
Abstract 4143083: Cardiomyopathy in Pregnancy Complicated by Loeys-Dietz Syndrome
Circulation
NOVEMBER 11, 2024
She was found to have atrial fibrillation and flutter with RVR. Cardiomyopathy and arrhythmia have been described in a small number of cases. Beta blockers and angiotensin receptor antagonists are used in slowing aortic dilatation; cardiomyopathy and arrhythmias should be treated according to established guidelines.
Prevalence and Predictors of Readmissions Among Patients with Hypertrophic Cardiomyopathy and Atrial Fibrillation/Flutter
The American Journal of Cardiology
APRIL 17, 2024
Publication date: Available online 16 April 2024 Source: The American Journal of Cardiology Author(s): Muhammad Usman Almani, Khawaja Muhammad Talha, Laibah Arhsad Khan, Ishaque Hameed, Zain Ul Abideen Asad, Marat Fudim, Richard Krasuski, Muhammad Shahzeb Khan
Abstract 4140664: From Atrial Fibrillation to Rare Genetic Disorder: The Unexpected Diagnosis of Birt-Hogg-Dubé Syndrome
Circulation
NOVEMBER 11, 2024
While studies have linked this genetic mutation to severe cardiac hypertrophy, a connection to persistent atrial fibrillation (AF) is unestablished. While no definitive link exists between BHDS and cardiomyopathy, we aim to understand possible connections between this rare condition and its systemic cardiovascular impacts.
Hypertrophic Cardiomyopathy
All About Cardiovascular System and Disorders
APRIL 30, 2024
Hypertrophic cardiomyopathy is a genetic disorder with a guarded prognosis which occurs in about 1:500 individuals. The most common symptom of hypertrophic cardiomyopathy is dyspnoea which occurs in 90% of cases and is due to elevated left ventricular diastolic pressures as a consequence of the diastolic dysfunction.
Paced QRS morphology mimicking complete left bundle branch block induced by right ventricular pacing is associated with pacing?induced cardiomyopathy
Journal of Cardiovascular Electrophysiology
MARCH 3, 2024
Complete left bundle branch block (CLBBB)-like QRS morphology of right ventricular pacing at pacemaker implantation satisfying the American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society criteria of CLBBB was associated with development of pacing induced cardiomyopathy.
Let's personalize your content